<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02613780</url>
  </required_header>
  <id_info>
    <org_study_id>20150570-01H</org_study_id>
    <nct_id>NCT02613780</nct_id>
  </id_info>
  <brief_title>Refractive Treatment of Early Keratoconus</brief_title>
  <official_title>iDesign Aberrometer for the Refractive Treatment of Early Keratoconus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Keratoconus is a bilateral, progressive corneal degenerative disorder that often leads to&#xD;
      significant visual deterioration over time. Corneal collagen crosslinking with riboflavin&#xD;
      (CXL) was developed as a treatment to halt the progression of keratoconus and thus negate the&#xD;
      need for corneal transplantation. However, the treatment alone has little impact in terms of&#xD;
      improving visual function. Photorefractive keratectomy (PRK) is the application of an excimer&#xD;
      laser to treat a patient's refractive error, therefore decreasing the dependence on&#xD;
      spectacles or contact lenses for improved vision.&#xD;
&#xD;
      Corneal collagen crosslinking combined with photorefractive keratectomy has been explored to&#xD;
      partially correct the refractive error in keratoconic patients, whilst simultaneously&#xD;
      stabilizing the corneal changes. Recently, the iDesign® Advanced WaveScan Studio (iDesign&#xD;
      system; Abbot Medical Optics; Santa Ana, CA) has been launched as the most advanced&#xD;
      high-resolution aberrometer. It is capable of mapping highly aberrated corneas for&#xD;
      wavefront-guided laser procedures, and represents an important technological advance in&#xD;
      treating corneal disease.&#xD;
&#xD;
      The purpose of this single center, prospective pilot study is to assess the safety and&#xD;
      efficacy of combined wavefront-guided PRK and CXL in patients with early keratoconus using&#xD;
      the iDesign® aberrometer. Results of this pilot study will be used to provide sample size&#xD;
      estimates for an extension of the study, which aims to determine whether sequential or same&#xD;
      day procedure leads to better outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this pilot study is to assess the visual outcomes of combined wavefront-guided&#xD;
      PRK and CXL in Krumeich stage 1 and 2 keratoconic eyes. The investigators will be conducting&#xD;
      a prospective study at the University of Ottawa Eye Institute. A total of 24 patients will be&#xD;
      enrolled in the study divided into two groups:&#xD;
&#xD;
      Group 1: PRK performed12-18 months after CXL; Group 2: PRK performed or on the same day as&#xD;
      CXL&#xD;
&#xD;
      Participants will be followed at regular intervals for 1 year and information regarding&#xD;
      visual, refractive, keratometric and higher order aberration outcomes will be collected.&#xD;
&#xD;
      The researchers aim to investigate the safety and efficacy of combined wavefront guided PRK&#xD;
      and CXL. Results of this pilot study will used to provide estimates for sample size&#xD;
      calculation for an extension of the study, which aims to determine whether sequential or same&#xD;
      day procedure leads to better outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in best-corrected visual acuity at followups</measure>
    <time_frame>1 year</time_frame>
    <description>Best-corrected visual acuity (BCVA) will be measured in logMAR. Preoperative BCVA will be compared to BCVA postoperatively and at followups over 1 year using paired t tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative and postoperative complications</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients with unexpected complications, as well as the type of complication will be collected over 1 year of followups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>Sequential group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Photorefractive keratectomy will be performed 12-18 months after participants had crosslinking</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simultaneous group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Photorefractive keratectomy and crosslinking will be performed on the same day</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Crosslinking</intervention_name>
    <description>corneal collagen crosslinking with riboflavin</description>
    <arm_group_label>Sequential group</arm_group_label>
    <arm_group_label>Simultaneous group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photorefractive keratectomy</intervention_name>
    <arm_group_label>Sequential group</arm_group_label>
    <arm_group_label>Simultaneous group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iDesign® Advanced WaveScan Studio</intervention_name>
    <description>Used to map wavefront aberration in planning photorefractive keratectomy</description>
    <arm_group_label>Sequential group</arm_group_label>
    <arm_group_label>Simultaneous group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group 1:&#xD;
&#xD;
        1. Patients with confirmed diagnosis of keratoconus in Krumeich stage 1 or 2 who have&#xD;
        received crosslinking 12-18 months prior, with follow up of at least 12 months&#xD;
&#xD;
        Group 2:&#xD;
&#xD;
          1. Diagnosis of keratoconus confirmed based on clinical examination findings and corneal&#xD;
             topography&#xD;
&#xD;
          2. Evidence of progression of keratoconus occurring over the last 12 months defined as:&#xD;
&#xD;
             i. An increase of maximum keratometry reading by 1 diopter or more (≥ 1 D), or ii.&#xD;
             Evidence of clinical progression&#xD;
&#xD;
          3. Age between 21 and 60 years&#xD;
&#xD;
          4. Eyes satisfying all of Krumeich stage 1 or 2 criteria listed below i. Stage 1:&#xD;
             eccentric corneal bulging, myopia, and/or astigmatism &lt;5 D and corneal radius ≤48 D,&#xD;
             no corneal opacities ii. Stage 2: myopia and/or astigmatism &gt;5 D and &lt;8 D and/or&#xD;
             corneal radius ≤53 D, no central opacities, pachymetry ≥400 μm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age less than 21 years, or older than 60 years&#xD;
&#xD;
          2. Pregnant, or planning to become pregnant, or breastfeeding&#xD;
&#xD;
          3. Past history of Herpes Simplex Keratitis or corneal surgery (other than crosslinking)&#xD;
&#xD;
          4. Thin Cornea (&lt;425 microns)&#xD;
&#xD;
          5. Other corneal disease, corneal scarring&#xD;
&#xD;
          6. History of chemical burns to the cornea or known healing problems&#xD;
&#xD;
          7. Known allergy to Riboflavin (vitamin B2)&#xD;
&#xD;
          8. If patient suffers from nystagmus or any other condition that would render it&#xD;
             difficult for the patient to hold a steady gaze&#xD;
&#xD;
          9. Very advanced corneal ectasia (beyond Krumeich stage 2)&#xD;
&#xD;
         10. Poor visual potential&#xD;
&#xD;
         11. Vitamin C supplements within 1 week of the procedure&#xD;
&#xD;
         12. Lenticular changes (cataracts)&#xD;
&#xD;
         13. Programmed PRK treatment exceeding 50 microns in tissue depth&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Setareh Ziai, MD, FRCSC</last_name>
    <email>ziaieye@gmail.com</email>
  </overall_contact>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <last_update_submitted>December 11, 2015</last_update_submitted>
  <last_update_submitted_qc>December 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

